Cargando…
Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma
Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum, graft...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175899/ https://www.ncbi.nlm.nih.gov/pubmed/25298592 http://dx.doi.org/10.4103/0253-7613.140598 |